Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004362743 | SCV004097167 | uncertain significance | not specified | 2023-06-15 | criteria provided, single submitter | clinical testing | The p.N102I variant (also known as c.305A>T), located in coding exon 1 of the EGLN1 gene, results from an A to T substitution at nucleotide position 305. The asparagine at codon 102 is replaced by isoleucine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |